{
    "clinical_study": {
        "@rank": "163092", 
        "acronym": "MAST", 
        "arm_group": [
            {
                "arm_group_label": "Metformin", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This study aims to see if metformin can delay the time to progression in men with low risk\n      prostate cancer when compared to a placebo."
        }, 
        "brief_title": "The Metformin Active Surveillance Trial (MAST) Study", 
        "completion_date": {
            "#text": "August 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Must be male > 18 and < 80 years of age\n\n          2. Have biopsy proven, low-risk, localized prostate cancer choosing expectant management\n             as primary treatment \u2264 1year. [For the purposes of assessing subject eligibility a\n             diagnostic biopsy must have included at least 10 cores, < 3 cores positive and < 50%\n             of any one core positive) and must have been obtained within 6 months of screening].\n             Initial diagnosis of T1a/T1b obtained during a TURP is not allowed\n\n          3. Gleason score \u2264 6 [Gleason pattern 4 or above must not be present on any biopsy\n             (initial or entry)]\n\n          4. Clinical stage T1c-T2a\n\n          5. Serum PSA \u226410 ng/mL (prior to biopsy)\n\n          6. Life expectancy greater than 5 years, as judged by the treating clinician/urologist\n\n          7. Able to swallow and retain oral medication\n\n          8. Hemoglobin A1c < 6.5%\n\n          9. Able and willing to participate in the full 3 years of the study\n\n         10. Able to understand instructions related to study procedures\n\n         11. Able to read and write (health outcome questionnaires are self-administered),\n             understand instructions related to study procedures and give written informed consent\n\n        Exclusion Criteria:\n\n          1. Subject that has ever been treated for prostate cancer with any of the following:\n\n               -  Radiotherapy (external beam or brachytherapy)\n\n               -  Chemotherapy\n\n               -  Hormonal therapy (e.g., megestrol, medoxyprogesterone, cyproterone)\n\n               -  Oral glucocorticoids\n\n               -  GnRH analogues (e.g., leuprolide, goserelin, degarelix)\n\n          2. Current and/or previous use of the following medications:\n\n               -  Use of 5\u03b1-reductase inhibitors (eg. Finasteride, Dutasteride) within the past 6\n                  months of screening\n\n               -  Drugs with antiandrogenic properties (e.g., flutamide, bicalutamide,\n                  ketoconazole, progestational agents) within 6 months prior to screening\n\n          3. Previous or current diagnosis of type 1 or type 2 diabetes\n\n          4. Exposure to metformin within 12 months of screening\n\n          5. Planned or concurrent use of metformin hydrochloride, sulfonylureas,\n             thiazolidinediones, or insulin for any reason\n\n          6. Known hypersensitivity or intolerance to metformin hydrochloride\n\n          7. Any condition associated with increased risk of metformin hydrochloride-associated\n             lactic acidosis (e.g. congestive heart failure defines as NYHA class III or IV,\n             history of any type of acidosis, habitual intake of \u2265 4 alcoholic beverages per day)\n\n          8. Subject has had prior prostatic surgery including TUNA, TURP, TUIP, laser treatment,\n             thermotherapy, balloon dilatation, prosthesis, and ultrasound ablation within 3\n             months of screening\n\n          9. Participation in any investigational or marketed drug trial within 30 days prior to\n             screening or anytime during the study period. This includes any interventional or\n             exercise trials\n\n         10. Any unstable serious co-existing medical condition(s) including, but not limited to,\n             myocardial infarction, coronary bypass surgery, unstable angina, cardiac arrhythmias,\n             clinically evident congestive heart failure, or cerebrovascular accident within 6\n             months prior to Screening visit\n\n         11. Abnormal liver function test:\n\n               -  Total bilirubin > 1.8 X institutional upper limit of normal (ULN)\n\n               -  Aspartate aminotransferase (AST) > 1.8 X institutional ULN\n\n               -  Alanine aminotransferase (ALT) > 1.8 X institutional ULN\n\n               -  Alkaline phosphatase (ALP) > 1.8 X institutional ULN\n\n         12. Serum creatinine > 1.8 X ULN\n\n         13. History of other malignancies, with the exception of adequately treated nonmelanoma\n             skin cancer, stage I melanoma, NMIBC or other solid tumors curatively treated with no\n             evidence of disease for at least 5 years\n\n         14. History or current evidence of substance abuse, as defined in DSM-IV, within 12\n             months of screening\n\n         15. History of any illness (including psychiatric) that, in the opinion of the\n             investigator, might confound the results of the study or pose additional risk to the\n             subject\n\n         16. No other concurrent metformin hydrochloride, sulfonylureas, thiazolidinediones, or\n             insulin for any reason"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "79 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "408", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01864096", 
            "org_study_id": "MAST 01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Metformin", 
                "description": "One month run-in of 850mg metformin once daily, followed by 850mg twice daily of metformin for 35 months. Total time is 36 months.", 
                "intervention_name": "Metformin", 
                "intervention_type": "Drug", 
                "other_name": "Metformin hydrochloride"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "One month run-in of placebo tablet once daily, followed by twice daily for 35 months. Total time is 36 months.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Placebo tablet"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Metformin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "localized", 
            "prostate", 
            "cancer", 
            "metformin", 
            "active surveillance"
        ], 
        "lastchanged_date": "March 17, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Winnipeg", 
                        "country": "Canada", 
                        "state": "Manitoba", 
                        "zip": "R3E 0V9"
                    }, 
                    "name": "Manitoba Cancer Care Centre"
                }, 
                "investigator": {
                    "last_name": "Darrel Drachenberg, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Halifax", 
                        "country": "Canada", 
                        "state": "Nova Scotia", 
                        "zip": "B2H 1Y6"
                    }, 
                    "name": "CDHA - Victoria Site"
                }, 
                "investigator": {
                    "last_name": "Ricardo Rendon, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hamilton", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "L8N 4A6"
                    }, 
                    "name": "McMaster Institute of Urology-St .Joseph's Healthcare"
                }, 
                "investigator": {
                    "last_name": "Bobby Shayegan, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kingston", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "K7L 3J7"
                    }, 
                    "name": "Centre for Appled Urologic Research, Kingston General Hospital"
                }, 
                "investigator": {
                    "last_name": "Michael Leveridge, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "N6A 5W9"
                    }, 
                    "name": "London Health Sciences Centre-Victoria Hospital"
                }, 
                "investigator": {
                    "last_name": "Jonathan Izawa, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M5G 2M9"
                    }, 
                    "name": "Princess Margaret Cancer Centre"
                }, 
                "investigator": [
                    {
                        "last_name": "Neil Fleshner, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Anthony Joshua, MD", 
                        "role": "Principal Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H2L 4M1"
                    }, 
                    "name": "Centre L'Hopitalie de l'Universite de Montreal"
                }, 
                "investigator": {
                    "last_name": "Fred Saad, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec"
                    }, 
                    "name": "MUHC - Montreal General Hospital"
                }, 
                "investigator": {
                    "last_name": "Simon Tanguay", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Quebec", 
                        "country": "Canada", 
                        "zip": "G1R 3S1"
                    }, 
                    "name": "Centre de Recherche Clinique et Evaluative en Oncologie (CRCEO)"
                }, 
                "investigator": {
                    "last_name": "Vincent Fradet, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-Blind, Placebo-Controlled Trial of Metformin in Reducing Progression Among Men on Expectant Management for Low Risk Prostate Cancer: The MAST (Metformin Active Surveillance Trial) Study", 
        "overall_contact": {
            "email": "ranjena.maloni@uhn.ca", 
            "last_name": "Ranjena Maloni, BSc", 
            "phone": "416-946-4501", 
            "phone_ext": "5859"
        }, 
        "overall_contact_backup": {
            "email": "karen.hersey@uhn.ca", 
            "last_name": "Karen Hersey, RN", 
            "phone": "(416) 946-2155"
        }, 
        "overall_official": [
            {
                "affiliation": "University Health Network: Department of Surgical Oncology (Urology)", 
                "last_name": "Neil Fleshner, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University Health Network: Department of Surgical Oncology (Urology)", 
                "last_name": "Anthony Joshua, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Time to progression - progression is defined as the earliest of the following events:\nPrimary therapy for prostate cancer (e.g. prostatectomy, radiation, hormonal therapy)\nPathological progression as defined as one of the following:\ni. At least 4 cores involved ii. At least 50% of any one core involved iii. Gleason pattern 4 or higher", 
            "measure": "Time to progression", 
            "safety_issue": "No", 
            "time_frame": "3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01864096"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Length of time before the participants move on to more radical treatment options (prostatectomy, radiation and/or hormonal therapy)", 
                "measure": "Time to primary therapy for prostate cancer", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "Time to pathological progression", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "description": "Measured by the Memorial Anxiety Scale for Prostate Cancer (MAX-PC)", 
                "measure": "Change from baseline in disease-related patient anxiety", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "description": "Measured by the Decisional Regret scale", 
                "measure": "Change from baseline in decisional satisfaction and decisional conflict", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "Change from baseline in prostate cancer diagnosis at repeat biopsy", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "Change in Gleason Score at repeat biopsy", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "Change in clinical stage of prostate cancer based on digital rectal examination", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "description": "Using biomarkers in tissue, blood and urine samples", 
                "measure": "Assess the prognostic and predictive value of prostate cancer biomarkers", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "To determine the safety and incidence of (serious) adverse events from the administration of 36 months of metformin to men with early stage prostate cancer", 
                "safety_issue": "Yes", 
                "time_frame": "3 years"
            }
        ], 
        "source": "University Health Network, Toronto", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University Health Network, Toronto", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}